Empirical and long-term therapy for endometriosis-associated pelvic pain

И. В. Кузнецова
In: Medical alphabet · 2021 · pp. 8–12 · doi:10.33667/2078-5631-2021-8-8-12 · W3166546933
article OA: hybrid CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This literature review examines current data on the prevalence, clinical features, and individualized therapy approaches for pelvic pain associated with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

The paper is a narrative literature review discussing the prevalence, clinical features, and how therapy is individually selected for women with diagnosed or suspected endometriosis-associated pelvic pain, focusing on empirical and long-term treatment approaches. It highlights that pelvic pain remains a central symptom and a management challenge due to difficulties identifying the pain source and the limited effectiveness of surgical and medication treatments. A key finding is the synthesis of contemporary data aimed at guiding individualized, long-term therapeutic selection, drawing on guidelines and prior studies. The major caveat is that it is a review rather than original clinical research, so conclusions reflect summarized literature and the paper does not provide new outcome measurements. This paper is centrally about endometriosis — it specifically addresses empirical and long-term therapy for endometriosis-associated pelvic pain.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a common disease, the diagnosis and treatment of which is still a matter of debate. One of the main symptoms of endometriosis -pelvic pain is a particular problem due to the difficulties in identifying the cause and the lack of sufficient effect from surgical and medical treatment. The literature review presents current data on the prevalence, clinical characteristics and methods of individualized therapy in patients with pelvic pain established or presumably associated with endometriosis.
Full text 10,685 characters · extracted from oa-html · click to expand
Эмпирическая и долговременная терапия тазовой боли, связанной с эндометриозом https://doi.org/10.33667/2078-5631-2021-8-8-12 Аннотация Эндометриоз является распространенным заболеванием, диагностика и терапия которого по-прежнему остаются предметом дискуссий Один из главных симптомов эндометриоза - тазовая боль представляет особую проблему в связи со сложностями выявления причины и отсутствием достаточного эффекта от хирургического и медикаментозного лечения. В обзоре литературы представлены современные данные о распространенности, клинической характеристике и методах индивидуального подбора терапии у пациенток с тазовой болью установленно или предположительно ассоциированной с эндометриозом. Об авторе И. В. КузнецоваРоссия Кузнецова Ирина Всеволодовна - доктор медицинских наук, профессор, советник директора. Москва. Список литературы 1. Klein S, D'Hooghe T, Meuleman C, Dirksen C, Dunselman G, Simoens S. What is the societal burden of endometriosis-associated symptoms? A prospective Belgian study. Reprod Biomed Online. 2014; 28 (1): 116-124. DOI: 10.1016/j.rbmo.2013.09.020. 2. Simoens S, Dunselman G, Dirksen C, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012; 27 (5): 1292-1299. DOI: 10.1093/humrep/des073. 3. Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014; 10 (5): 261-275. DOI: 10.1038/nrendo.2013.255. 4. Soliman AM, Coyne KS, Zaiser E, Castelli-Haley J, Fuldeore MJ. The burden of endometriosis symptoms on health-related quality of life in women in the United States: a cross-sectional study. J Psychosom Obstet Gynaecol. 2017; 38 (4): 238-248. DOI: 10.1080/0167482X.2017.1289512. 5. Parazzini F, Esposito G, Tozzi L, Noli S, Bianchi S. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol. 2017; 209: 3-7. DOI: 10.1016/j.ejogrb.2016.04.021. 6. Powell J. The approach to chronic pelvic pain in the adolescent. Obstet Gynecol Clin North Am. 2014; 41 (3): 343-355. DOI: 10.1016/j.ogc.2014.06.001. 7. Fuldeore MJ, Soliman AM. Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. Gynecol Obstet Invest. 2017; 82 (5): 453-461. DOI: 10.1159/000452660. 8. Singh S, Soliman AM, Rahal Y, Robert C, Defoy I, Nisbet P, Leyland N. Prevalence, Symptomatic Burden, and Diagnosis of Endometriosis in Canada: Cross-Sectional Survey of 30 000 Women. J Obstet Gynaecol Can. 2020; 42 (7): 829-838. DOI: 10.1016/j.jogc.2019.10.038. 9. Эндометриоз: диагностика, лечение и реабилитация: Федеральные клинические рекомендации по ведению больных. М.: МЗ РФ, 2016. 10. Muzii L, Marana R, Angioli R, Bianchi A, Cucinella G, Vignali M, Benedetti Panici P, Busacca M. Histologic analysis of specimens from laparoscopic endometrioma excision performed by different surgeons: does the surgeon matter? Fertil Steril. 2011; 95 (6): 2116-2119. DOI: 10.1016/j.fertnstert.2011.02.034. 11. Mowers EL, Lim CS, Skinner B, Mahnert N, Kamdar N, Morgan DM, As-Sanie S. Prevalence of Endometriosis During Abdominal or Laparoscopic Hysterectomy for Chronic Pelvic Pain. Obstet Gynecol 2016; 127 (6): 1045-1053. 12. Gubbels AL, Li R, Kreher D, Mehandru N, Castellanos M, Desai NA, Hibner M. Prevalence of occult microscopic endometriosis in clinically negative peritoneum during laparoscopy for chronic pelvic pain. Int J Gynaecol Obstet. 2020; 151 (2): 260-266. DOI: 10.1002/ijgo.13303. 13. Goodman LR, Goldberg JM, Flyckt RL, Gupta M, Harwalker J, Falcone T. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls. Am J Obstet Gynecol. 2016; 215 (5): 589.e1-589.e6. DOI: 10.1016/j.ajog.2016.05.029. 14. Streuli I, de Ziegler D, Gayet V, Santulli P, Bijaoui G, de Mouzon J, Chapron C. In women with endometriosis anti-Mullerian hormone levels are decreased only in those with previous endometrioma surgery. Hum Reprod. 2012; 27: 3294-3303. 15. Sugita A, Iwase A, Goto M, et al. One-year follow-up of serum antimullerian hormone levels in patients with cystectomy: are different sequential changes due to different mechanisms causing damage to the ovarian reserve? Fertil Steril. 2013; 100 (2): 516-522.e3. DOI: 10.1016/j.fertnstert.2013.03.032. 16. Ferrero S, Scala C, Racca A, Calanni L, Remorgida V, Venturini PL, Leone Roberti Maggiore U. Second surgery for recurrent unilateral endometriomas and impact on ovarian reserve: a case-control study. Fertil Steril. 2015; 103 (5): 1236-1243. DOI: 10.1016/j.fertnstert.2015.01.032. 17. Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29 (3): 400-412. DOI: 10.1093/humrep/det457. 18. Sieberg CB, Lunde CE, Borsook D. Endometriosis and pain in the adolescentstriking early to limit suffering: A narrative review. Neurosci Biobehav Rev. 2020; 108: 866-876. DOI: 10.1016/j.neubiorev.2019.12.004. 19. Антоненко М. В., Сапрыкина О. А. Использование агонистов гонадотропных рилизинг-гормонов в терапии эндометриоза. Эффективная фармакотерапия. Акушерство и гинекология. 2012; 1: 34-35. 20. Reis FM, Coutinho LM, Vannuccini S, Batteux F, Chapron C, Petraglia F. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020 Jun 18; 26 (4): 565-585. DOI: 10.1093/humupd/dmaa009. 21. Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest regulates apoptosis, proliferation, and invasiveness of endometriotic cyst stromal cells via endoplasmic reticulum stress induction. Mol Hum Reprod. 2020; 26 (1): 30-39. DOI: 10.1093/molehr/gaz064. 22. Mita S, Shimizu Y, Sato A, Notsu T, Imada K, Kyo S. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β. Fertil Steril. 2013; 101 (2): 595–601. DOI: 10.1016/j.fertnstert.2013.10.038. 23. Miyashita M, Koga K, Takamura M, et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol Endocrinol 2014; 30 (9): 644-648. DOI: 10.3109/09513590.2014.911279. 24. Takeuchi A, Koga K, Miyashita M, et al. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis. Eur J Obstet Gynecol Reprod Biol. 2016; 207: 157-161. DOI: 10.1016/j.ejogrb.2016.10.053. 25. Ichioka M, Mita S, Shimizu Y, Imada K, Kiyono T, Bono Y, Kyo S. Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells. J Steroid Biochem Mol Biol. 2015; 147: 103-110. DOI: 10.1016/j.jsbmb.2014.12.008. 26. Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016; 65 (3): 183-192. DOI: 10.1007/s00011-015-0909-7. 27. Mabrouk M, Paradisi R, Arena A, Del Forno S, Matteucci C, Zannoni L, Caprara G, Seracchioli R. Short-term histopathological effects of dienogest therapy on ovarian endometriomas: in vivo, nonrandomized, controlled trial. Gynecol Endocrinol. 2018; 34 (5): 399-403. DOI: 10.1080/09513590.2017.1405932. 28. Del Forno S, Mabrouk M, Arena A, Mattioli G, Giaquinto I, Paradisi R, Seracchioli R. Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas: Can we avoid surgery? Eur J Obstet Gynecol Reprod Biol. 2019; 238: 120-124. DOI: 10.1016/j.ejogrb.2019.04.010. 29. Kitajima M, Matsumoto K, Murakami N, Harada A, Kitajima Y, Masuzaki H, Miura K. Ovarian reserve after three-step laparoscopic surgery for endometriomas utilizing dienogest: A pilot study. Reprod Med Biol. 2020; 19 (4): 425-431. DOI: 10.1002/rmb2.12349. 30. Angioni S, Pontis A, Malune ME, Cela V, Luisi S, Litta P, Vignali M, Nappi L. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020; 36 (1): 84-86. DOI: 10.1080/09513590.2019.1640674. 31. Muzii L, Galati G, Di Tucci C, Di Feliciantonio M, Perniola G, Di Donato V, Benedetti Panici P, Vignali M. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol. 2020; 36 (1): 81-83. DOI: 10.1080/09513590.2019.1640199. 32. Тихонова Е. С. Медицинские и социальные аспекты генитального эндометриоза: Автореф. дис. ... канд. мед. наук. М., 2013; 26 с. 33. Кузнецова И. В. Эндометриоз и тазовая боль: что мы лечим? О природе болевого синдрома при эндометриозе и возможностях терапии. Status Praesens. Гинекология, акушерство, бесплодный брак. 2015; 1 (27): 50-54. 34. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014; 101 (4): 927-935. DOI: 10.1016/j.fertnstert.2014.02.012. 35. Caruso S, Iraci M, Cianci S, Fava V, Casella E, Cianci A. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 pg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 39 (8): 923-931. DOI: 10.1007/s40618-016-0460-6. 36. Vercellini P, Eskenazi B, Consonni D, Somigliana E, Parazzini F, Abbiati A, Fedele L. Oral contraceptives and risk of endometriosis: a systematic review and me-ta-analysis. Hum Reprod Update. 2011; 17 (2): 159-170. DOI: 10.1093/humupd/dmq042. 37. Chapron C, Souza C, Borghese B, Lafay-Pillet MC, Santulli P, Bijaoui G, Goffinet F, de Ziegler D. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod. 2011; 26 (8): 2028-2035. DOI: 10.1093/humrep/der156. 38. Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018; 51: 68-91. DOI: 10.1016/j.bpobgyn.2018.01.015. Рецензия Для цитирования: Кузнецова И.В. Эмпирическая и долговременная терапия тазовой боли, связанной с эндометриозом. Медицинский алфавит. 2021;(8):8-12. https://doi.org/10.33667/2078-5631-2021-8-8-12 For citation: Kuznetsova I.V. Empirical and long-term therapy for endometriosis-associated pelvic pain. Medical alphabet. 2021;(8):8-12. (In Russ.) https://doi.org/10.33667/2078-5631-2021-8-8-12 JATS XML

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (34)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK